EUVIMEDEUVIMED entdecken
Crossref

Glucagon‐Like Peptide‐1 Receptor Agonists and Incident Cardiovascular Events and Death in Treated Serious Mental Illness, Type 2 Diabetes, and Obesity

Samuel B Governor iD, David M Dávila-García, Eliut Rivera-Segarra iD, Lindsey M Filiatreau iD, Nelmit Tollinchi-Natali iD, Ekow Essien iD, Osamah Altaee iD, Prince Otchere, Leopoldo J Cabassa iD, Victor G Dávila-Román iD

Journal of the American Heart Association · 20.10.2026 · 15 (20)

DOI: 10.1161/jaha.126.051982 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the American Heart Association, erschienen am 20.10.2026. Verfasst von Samuel B Governor und 9 weiteren Autor:innen. Beteiligte Einrichtung: St. John's Episcopal Hospital New York NY USA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Glucagon-Like Peptide-1 Receptor Agonists, Obesity, Mental Disorders. Die Arbeit nennt 47 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Adults with serious mental illness (SMI), type 2 diabetes, and obesity have elevated cardiovascular risk. Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) have established cardiometabolic benefits in the general population, but their effects in SMI are unclear. We evaluated whether GLP‐1RA use was associated with lower risks of incident myocardial infarction (MI), heart failure (HF), and all‐cause death.

Methods

This was a retrospective propensity score–matched cohort study of 218 043 adults with SMI, type 2 diabetes, obesity, and active antipsychotic or antidepressant medications in the TriNetX database (73 health care organizations). Outcomes were incident MI, HF, and all‐cause death at 1 and 3 years. The primary exposure was GLP‐1RA use versus nonuse; secondary analyses examined semaglutide or tirzepatide. Exploratory analyses evaluated sex, race, and sodium–glucose cotransporter‐2 inhibitor and dipeptidyl peptidase‐4 inhibitor use.

Results

GLP‐1RA use was associated with lower risks of incident MI, HF, and all‐cause death. Risk differences at 1 and 3 years were −0.007 and −0.010 for MI, −0.011 and −0.018 for HF, and −0.039 and −0.065 for death (all P

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Glucagon-Like Peptide-1 Receptor AgonistsObesityMental DisordersHypoglycemic AgentsMyocardial InfarctionHeart FailureIncretinsCardiovascular DiseasesHumansMaleFemaleRetrospective StudiesMiddle AgedSemaglutideTirzepatideIncidenceAgedAntipsychotic AgentsUnited StatesCause of DeathRisk AssessmentGlucagon-Like PeptidesRisk FactorsAdultTime FactorsAntidepressive Agents

Stichwörter der Autor:innen

cardiovascular outcomesdeathglucagon‐like peptide‐1 receptor agonistsheart failuremyocardial infarctionobesitysemaglutideserious mental illnesstirzepatidetype 2 diabetes

Substanzen

Glucagon-Like Peptide-1 Receptor AgonistsSemaglutideTirzepatideAntipsychotic AgentsHypoglycemic AgentsGlucagon-Like PeptidesIncretinsAntidepressive Agents

Autor:innen und Institutionen

  • St. John's Episcopal Hospital New York NY USA.
  • Institute for Informatics, Data Science and Biostatistics Washington University School of Medicine St. Louis MO USA.
  • School of Behavioral and Brain Sciences Ponce Health Sciences University Ponce PR USA.
  • Bursky School of Public Health Washington University in St. Louis St. Louis MO USA.
  • School of Dental Medicine Ponce Health Sciences University Ponce PR USA.
  • Aurora Health Care Kenosha WI USA.

ORCID-Profile: Samuel B Governor, Eliut Rivera-Segarra, Lindsey M Filiatreau, Nelmit Tollinchi-Natali, Ekow Essien, Osamah Altaee, Leopoldo J Cabassa, Victor G Dávila-Román

Zitieren

APA

Governor, S. B., Dávila-García, D. M., Rivera-Segarra, E., Filiatreau, L. M., Tollinchi-Natali, N., Essien, E., Altaee, O., Otchere, P., Cabassa, L. J., & Dávila-Román, V. G. (2026). Glucagon‐Like Peptide‐1 Receptor Agonists and Incident Cardiovascular Events and Death in Treated Serious Mental Illness, Type 2 Diabetes, and Obesity. Journal of the American Heart Association, 15(20). https://doi.org/10.1161/jaha.126.051982

Vancouver

Governor SB, Dávila-García DM, Rivera-Segarra E, Filiatreau LM, Tollinchi-Natali N, Essien E, et al. Glucagon‐Like Peptide‐1 Receptor Agonists and Incident Cardiovascular Events and Death in Treated Serious Mental Illness, Type 2 Diabetes, and Obesity. Journal of the American Heart Association. 2026;15(20). doi:10.1161/jaha.126.051982

BibTeX
@article{Governor2026,
  author = {Governor, Samuel B and Dávila-García, David M and Rivera-Segarra, Eliut and Filiatreau, Lindsey M and Tollinchi-Natali, Nelmit and Essien, Ekow and Altaee, Osamah and Otchere, Prince and Cabassa, Leopoldo J and Dávila-Román, Victor G},
  title = {Glucagon‐Like Peptide‐1 Receptor Agonists and Incident Cardiovascular Events and Death in Treated Serious Mental Illness, Type 2 Diabetes, and Obesity},
  journal = {Journal of the American Heart Association},
  year = {2026},
  volume = {15},
  number = {20},
  doi = {10.1161/jaha.126.051982}
}
Kostenlos starten →